https://teknolabjournal.com/index.php/Jtl <p><iframe style="border: 0px #ffffff none;" src="https://author.my.id/widget/statistik.php?sinta=391&amp;gs=feWOwRkAAAAJ&amp;hl&amp;sc=9" name="statistik" width="100%" height="250px" frameborder="0" marginwidth="0px" marginheight="0px" scrolling="no"></iframe></p> <p style="text-align: justify;"><em>Jurnal Teknologi Laboratorium</em>, with registered number ISSN 2<a href="http://issn.pdii.lipi.go.id/issn.cgi?daftar&amp;1369726769&amp;1&amp;&amp;" target="_blank" rel="noopener">338-5634&nbsp;(print)</a>, <a href="http://issn.pdii.lipi.go.id/issn.cgi?daftar&amp;1493892253&amp;1&amp;&amp;" target="_blank" rel="noopener">2580-0191&nbsp;(online)</a>&nbsp;is a scientific journal published by&nbsp;Poltekkes Kemenkes Yogyakarta. The journal <span class="st">registered in the CrossRef system </span><span class="il">with </span><strong><span class="st">Digital Object Identifier </span><span class="il">(DOI)</span> prefix <a href="https://search.crossref.org/?q=2580-0191&amp;publication=Jurnal+Teknologi+Laboratorium" target="_blank" rel="noopener">10.29238.</a>&nbsp;</strong>&nbsp;The aim of this journal publication is to disseminate the conceptual thoughts or ideas and research results that have been achieved in the area of medical laboratory sciences.&nbsp; Every article that goes to the editorial staff will be selected through <strong>Initial Review</strong> processes by the Editorial Board. Then, the articles will be sent to the peer reviewer and will go to the next selection by Double-Blind<strong> Peer - review Process</strong>. After that, the articles will be returned to the authors to revise. These processes take 6 - 7 months for maximum time. In each manuscript, the peer reviewer will be rated from the substantial and technical aspects. The final decision of article acceptance will be made by Editors according to the Reviewer's comments. The reviewer that collaboration with <em>Jurnal Teknologi Laboratorium</em>&nbsp;is the experts in the medical laboratory technology&nbsp;area and issues around it.</p> <p style="text-align: justify;"><em>Jurnal Teknologi Laboratorium</em> particularly focuses on the main problems in the development of the sciences of medical laboratory&nbsp;areas. It covers parasitology, bacteriology, virology, hematology, clinical chemistry, toxicology, food, and drink chemistry <strong>but for special issues</strong>, it is possible to receive another area of health like epidemiology, etc.</p> <p style="text-align: justify;">In order to further internationalize our journal, Jurnal Teknologi Laboratorium has decided to change the Indonesian language to<strong> accept the English </strong>language only, since 2019.</p> <p style="text-align: justify;"><strong>Please read these guidelines carefully</strong>. &nbsp;Authors who want to submit their&nbsp;manuscript to the editorial office of&nbsp;<em>Jurnal Teknologi Laboratorium</em>&nbsp;should obey the writing guidelines. If the&nbsp;manuscript submitted is not appropriate with the guidelines or written in a different format, <strong>it will&nbsp;BE REJECTED</strong> by the editors before further reviewed. The editors will only accept the manuscripts which meet the assigned format.</p> <table style="background-color: #ccffff; margin: 20px auto 15px;" width="100%"> <tbody> <tr> <td style="width: 100%; text-align: center;"> <h2 style="margin-top: 15px; text-transform: uppercase;">Statistics</h2> </td> </tr> <tr> <td style="width: 581px;"> <p style="padding-left: 30px;"><strong>Volume 8 No 1. 2019:</strong></p> <p style="padding-left: 30px;">Articles Received: 15; Accepted: 7; Rejected: 7; Published: 6; Retracted: 0</p> <p><strong>&nbsp; &nbsp; &nbsp; &nbsp;Volume 7 No 2. 2018:</strong></p> <p>&nbsp; &nbsp; &nbsp; &nbsp;Articles Received: 11; Accepted: 6; Rejected: 5; Published: 5; Retracted: 0</p> </td> </tr> </tbody> </table> en-US <p style="text-align: justify;">Publishing your paper with Jurnal Teknologi Laboratorium&nbsp;(JTL)&nbsp;means that the author or authors retain the copyright in the paper. JTL&nbsp;granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL&nbsp;in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.</p> <p style="text-align: justify;">JTL&nbsp;journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under&nbsp;a&nbsp;<a href="http://creativecommons.org/licenses/by-sa/4.0/" rel="license">Creative Commons Attribution-ShareAlike 4.0 International License</a>.&nbsp;This license lets others remix, transform, and build upon the material&nbsp;for any purpose, even commercially.</p> <p style="text-align: justify;">JTL&nbsp;journal Open Access articles are distributed under this <strong><a href="http://creativecommons.org/licenses/by-sa/4.0/" rel="license">Creative Commons Attribution-ShareAlike 4.0 International License</a>&nbsp;(CC BY-SA).</strong>&nbsp;Articles can be read and shared for All&nbsp;purposes under the following conditions:</p> <ul> <li class="show" style="text-align: justify;"><em>BY:</em>&nbsp;You must give <a id="appropriate_credit_popup" class="helpLink" href="https://creativecommons.org/licenses/by-sa/4.0/#">appropriate credit</a>, provide a link to the license, and&nbsp;<a id="indicate_changes_popup" class="helpLink" href="https://creativecommons.org/licenses/by-sa/4.0/#">indicate if changes were made</a>. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</li> <li class="show" style="text-align: justify;"><em>SA:</em>&nbsp; If you remix, transform, or build upon the material, you must distribute your contributions under the <a id="same_license_popup" class="helpLink" href="https://creativecommons.org/licenses/by-sa/4.0/#">same license</a> as the original.</li> </ul> budi.setiawan@poltekkesjogja.ac.id (Budi Setiawan) doraturistaofficial@gmail.com (Dora Dayu Rahma Turista) Tue, 30 Apr 2024 22:21:30 +0700 OJS 3.3.0.8 http://blogs.law.harvard.edu/tech/rss 60 https://teknolabjournal.com/index.php/Jtl/article/view/479 <p>Elderly patients are at a high risk of developing chronic diseases, including cardiovascular disease, cancer, dementia, and diabetes. Additionally, many elderly individuals experience multimorbidity, having more than one chronic condition, contributing to the phenomenon of polypharmacy. This case report aims to analyze polypharmacy therapy in elderly patients with concurrent decreased kidney function and elevated liver enzymes. Polypharmacy in elderly patients with decreased kidney and liver function necessitates a comprehensive study to assess both its benefits and potential side effects. Monitoring should be implemented to detect any emergence of side effects or drug interactions resulting from the prescribed therapy. According to the 2023 Beers Criteria, elderly patients with reduced kidney function face an elevated risk of drug-related side effects, potentially leading to prolonged hospital stays and increased medical costs.</p> Marisca Evalina Gondokesumo Copyright (c) 2024 Marisca Evalina Gondokesumo https://creativecommons.org/licenses/by-sa/4.0 https://teknolabjournal.com/index.php/Jtl/article/view/479 Tue, 30 Apr 2024 00:00:00 +0700